Prevalence of SARS-CoV-2 antibodies in the Republic of Congo in mid-2021.
IJID Reg
; 5: 121-123, 2022 Dec.
Article
en En
| MEDLINE
| ID: mdl-36217501
ABSTRACT
Objectives:
To estimate the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies in the general population in the Republic of Congo.Methods:
In this cross-sectional study, conducted from June to July 2021, participants were recruited from the general population in three districts in the Republic of Congo. Eligible participants were tested for anti-SARS-CoV-2 antibodies using a rapid diagnostic assay.Results:
Overall, 31.8% [95% confidence interval (CI) 29.5-34.0] of the 1669 participants tested positive for anti-SARS-CoV-2 antibodies. Higher prevalence was observed in the rural region (37.3%, 95% CI 31.0-44.1%) than the urban region (30.9%, 95% CI 28.5-33.3); however, the difference was not significant. The risk of testing positive for anti-SARS-CoV-2 antibodies increased significantly with age, ranging from 22.5% (95% CI 18.1-27.5) in 15-24 year olds to 47.9% (95% CI 39.3-56.5) in 55-64 year olds.Conclusions:
The antibody levels observed in this survey correlate with a moderate rate of virus circulation, which correlates with the low number of confirmed cases of coronavirus disease 2019 in the Republic of Congo.
Texto completo:
1
Banco de datos:
MEDLINE
Tipo de estudio:
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Idioma:
En
Año:
2022
Tipo del documento:
Article